Offer Brief · offer evaluatorCareer IntelligenceFiled · Sep 14, 2026 · Confidential

Subject company

Pfizer Inc.

Director, Clinical Data Science · Global Job Level 11 · Cambridge, MA

Negotiate before signing; use the leverage page anchors. Base is already at the high end of the market band, so the most productive asks are the equity grant size, the target bonus percentage (not yet disclosed), and vesting and refresh terms — ask about each explicitly before you sign.

Pfizer Inc.: Rule of 40 at 8.2 and a $300,000 package (base plus equity plus signing) at 1.8× the base-cash median — FAIR verdict, negotiate before signing.

Base

$215K

Equity grant

$55K

Vest

4 yr · cliff 1

Offer vesting schedule

Market band · DOL H-1B / LCA

Data Scientists · Level IV · Massachusetts

This offer’s base sits at the 90th percentile — above nearly every certified filing in this band.

Role-specific match

P25

$149K$148,762

Median

$163K$162,634

P75

$188K$187,975

P90

$215K$214,900

Your base: $215,000 · $27,026 above the P75 mark — this band is a floor under you, not a ceiling

Source: DOL OFLC LCA disclosure data · n=203 certified filings · base cash only (excludes equity and bonus). Use as a citable market floor, not total compensation.

The return on this brief

$3K / yr recurring

$17K one-time

The negotiation room this brief is built to unlock — typically many multiples of its price. The lever-by-lever play is in the negotiation playbook below.

Mixed

company trajectory · low confidence

One number that matters

$874K

5-year expected total comp (probability-weighted NPV)

bear

$851K

base

$871K

bull

$915K

What moves this number

Nominal (undiscounted) 5-year total under the base scenario: $1,141,667
Discount rate applied to every year: 10%
Annual target bonus: NOT PROVIDED at intake — every year below is base (plus signing and vesting equity) alone. No bonus was assumed.
Vesting over 3 years with 1-year cliff
Bear equity multiple: 0.3x
Base equity multiple: 1.0x
Bull equity multiple: 2.5x
Exit probabilities: bear 30%, base 50%, bull 20%

01 · Executive decision

What to do next

Start here. This section compresses the brief into the decision, the strongest reasons behind it, and the risks that deserve verification before you sign.

Why the verdict landed here

Base $215,000 sits at the 90th percentile of the base-cash market band (median $162,634).
Company operating quality is weak (Rule of 40: 8.2).
Base sits at the 90th percentile of the certified base-cash band for Massachusetts (n=203).
Growth-and-margin composite of 8 (2.6% revenue growth plus 5.6% FCF margin) — an adapted screen: the 40 threshold is a SaaS convention this company is read against, not a bar it was set.

Signals we only see when the data is connected

The CFO vacancy and a dividend payout ratio above 100% together make the RSU grant far riskier than the headline number suggests — a $26 stock price would cut the $55,000 grant to roughly $51,500, and there is no permanent finance leader to defend the R&D budget that funds this role.

high

Negotiation leverage + Risks + Career upside · medium confidence · 2 source facts in the appendix

Pfizer's headcount fell from 88,000 to 75,000 between 2023 and 2025 — a 15% reduction — yet the five-year forecast's base case treats organizational trajectory as stable; the combination of a Rule of 40 score of just 8 and a peer financial health score of 43 against a peer median of 71 makes a further contraction of the Clinical Data Science function the more probable scenario, not the exception.

high

Company quality + Career upside + Employer durability + Risks · medium confidence · 3 source facts in the appendix

CEO Albert Bourla's open-market buy and option-exercise-hold signal personal confidence in the stock, but a single insider's positive posture sits against an opportunistic sell by another named executive and a stock annualized volatility of 23.6% with a maximum 12-month drawdown of -17.1% — the insider signal is too thin to offset the equity risk embedded in a 3-year RSU vest at current prices.

medium

Leadership and stability + Company quality + Negotiation leverage · medium confidence · 3 source facts in the appendix

Pfizer's $22.65M lobbying spend across 47 filings — concentrated on healthcare reform, trade, and pharmaceutical issues — signals that a meaningful share of the company's strategic energy is directed at regulatory defense rather than organic growth; paired with revenue growth of just 2.6% against a peer median of 5.7%, this pattern suggests the merit-increase and equity-refresh budgets available to a Director-level hire are structurally constrained, making the three questions about bonus payout history and refresh cadence more consequential than they appear.

medium

Company quality + Questions to ask + Offer economics · medium confidence · 3 source facts in the appendix

Unlock 3 more signals only Footnote connects

Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.

Get the Offer Brief — $49 Compare both brief tiers

Score components

Org health · 36%43

Leadership · 21%79

no SEC graph — neutral prior

Strategy · 21%75

Alumni · 0%55

not weighted in this composite — no evidence to score it

Promotion · 0%55

not weighted in this composite — no evidence to score it

Skills · 14%55

no skills signal — neutral prior

Red flags · 7%30

Bar color: strong (65+) · moderate (45–64) · weak (<45)

Higher is healthier on every bar — including Red flags, where a high score means few were raised

55% of the design weighting is not evidence-backed — 30% was renormalized out of the composite entirely and 25% is still weighted but scored on a neutral prior. The percentages above are the weights this score was actually computed with.

Purchase your report to unlock full details

Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.

Get the Offer Brief — $49 Compare both brief tiers

The decision rule

Negotiate first

Derived from this brief’s own numbers — the band placement, company operating quality, and role exposure — not model judgment. The same rule fixes the verdict above.

Accept when

Comp is already placed above market — protect it; negotiate scope, level, or refresh terms instead of base.
The equity-weighted package (base plus equity plus signing) stays ≥ 1.5× the base-cash median (currently 1.8×).

Negotiate when

Equity is the swing factor — confirm the refresh policy and vest mechanics before relying on the headline number.

Walk away when

Company fundamentals stay weak (Rule of 40 8) AND they won't trade cash certainty (base/signing) for back-loaded equity.

Where people from here go next

Alumni outcomes require optional user-contributed career data and confidence thresholds.

02 · Offer economics

What the offer is really worth

This translates the package into realized value, equity risk, market benchmarks, and concrete negotiation room.

Headline package

$300K

base plus equity plus signing

After cliff year 1

$282K

Equity scenario spread

32.7%

Negotiation room

Base 5% / equity 15%

Market consensus

A compact read on whether public-market expectations support the equity story behind the offer.

Median target

$27

DCF fair value

$34

Revenue est. · FY2026

$62.2B

Grade momentum · 1 upgrade / 1 downgrade / 13 reaffirmations in 180d

HSBC: downgrade

Jul 06, 2026 · Buy → Hold

RBC Capital: upgrade

Jun 10, 2026 · Underperform → Sector Perform

Total comp at three valuations

Your $215,000 base sits at the 90th percentile of the Massachusetts base-cash market band (DOL H-1B/LCA, n=203, median $162,634), so base is the weakest negotiating angle — the more productive ask is the $55,000 RSU grant, where a 15% increase to roughly $63,250 is defensible given Pfizer's own NEO equity weighting and the bear-case RSU scenario of $51,513 at a $26 stock price. The headline package of $300,000 (base plus equity plus signing) is 1.8× the base-cash median, but the BEA regional price parity index for Massachusetts (105.757) means your nominal dollars carry roughly 94.6 cents of national purchasing power — worth factoring into any relocation or cost-of-living framing before you finalize. Equity scenarios use rsu linear and show 32.7% spread across available public valuation anchors.

Evidence confidence: high

Highest leverage asks

Base sits at 90th percentile — equity is thin: Your $215,000 base clears the Massachusetts base-cash market band median of $162,634 by a wide margin and lands at the 90th percentile of that 203-observation band — so base is not where the gap lives. The $55,000 RSU grant is where the offer underdelivers relative to the seniority implied by Global Job Level 11: at a 3-year vest, that is roughly $18,333 in equity per year before any price movement, a figure that does not reflect the strategic weight Pfizer's own earnings call placed on AI-driven R&D acceleration — exactly the domain a Director of Clinical Data Science owns. Ask whether the equity grant can be increased to better reflect the level's scope.

Evidence confidence: medium

Signing bonus is one-time — ask about bonus target: The $30,000 signing bonus is a non-recurring payment; once it clears, your annual run-rate drops to base plus whatever annual incentive Pfizer attaches to this level. The offer as collected carries no target bonus percentage, which means a material component of your ongoing total compensation is unquantified. Before signing, ask what the annual incentive target is as a percentage of base for Global Job Level 11 — that figure, applied to $215,000, could represent $30,000–$50,000 or more per year and belongs in any honest comparison of this offer to alternatives.

Evidence confidence: medium

Pfizer's growth lags peers — equity upside is constrained: Pfizer's revenue grew 2.6% over the twelve months from 2025-06-29 to 2026-06-28, against a peer-group median of 5.7% across the 7 qualifying Drug Manufacturers - General peers examined. The composite of that growth rate and FCF margin of 5.6% produces a Rule of 40 score of 8.2 — a weak reading for a large-cap pharma, though the 40-point threshold is a SaaS convention and should be read as a composite signal rather than a pass/fail. The equity scenario analysis puts your bear-case RSU value at $51,513 (at a $26 share price) and the base case at $53,494 (at $27) — a spread of only $1,981 between bear and base, reflecting limited near-term price catalyst. The bull case reaches $68,348 only if the DCF fair value of $34.50 is realized. Use the constrained upside to argue for a larger grant size rather than a higher base.

Evidence confidence: medium

Executive compensation context

The FY2025 DEF 14A shows CEO Albert Bourla at $27.6M total (salary $1.8M, stock awards $9.4M, option awards $9.0M, incentive plan $5.4M); the four other named executives ranged from $9.1M (Lankler) to $10.0M (Boshoff), with equity — stock plus options — comprising roughly 45–55% of each NEO's total. The structure confirms that Pfizer tilts director-and-above pay heavily toward long-dated equity, which is the context for evaluating a $55,000 RSU grant at Global Job Level 11.

From proxy-statement compensation records.

Insider exercise pattern

In the trailing 90 days, Form 4 filings show a net-buying posture: 3 open-market buy trades against 1 open-market sell trade (1 distinct seller, 3,278 shares totaling approximately $83.3K), with 12 equity awards and 0 tax-withholding rows excluded as non-discretionary — overall signal strength is low given the small sample. The buy-side activity includes director-level open-market purchases, which reflects some confidence at the board level, but the window is too short and the volume too modest to draw a directional conclusion about stock trajectory.

Pattern read derived from Form 4 filing data.

Comp waterfall

What it shows

Headline package versus the modeled value after the first vesting cliff.

Why it matters

It separates advertised compensation from what is actually exposed to vesting timing.

How to use it

Anchor negotiation around the gap between headline value and first-year realized value.

Equity scenarios

bear

$52K

base

$53K

bull

$68K

Cliff risk: leave before the first vesting cliff and realized equity is $0 — the bear case is not the floor. Weigh signing cash accordingly.

What it shows

Bear, base, and bull public-market anchors for the equity grant.

Why it matters

RSU value is not fixed. A strong offer can still carry material downside if the stock resets.

How to use it

Ask for equity refresh protection, a higher grant, or signing cash if downside exposure is high.

External comp benchmarks

Directional public-market anchors — not company-specific exec comp or your offer.

DOL H-1B / LCA · state + level

Massachusetts · n=203 · offer at 90th pctRole-specific match

P10: $148,762
P25: $148,762
Median: $162,634
P75: $187,975
P90: $214,900

Base cash only (year) — excludes equity and bonus.

BLS OEWS floor — Data Scientists, Massachusetts (state OEWS) (2025): median $131,750. Government survey median; a conservative floor, not the role-and-metro market the band above reflects.

Peer tickers are selected from public market data and filings — use as directional context, not a compensation survey.

Not available for this run: next earnings date. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.

Sponsorship posture · federal petition outcomes

Growing — new sponsored-hire approvals rose in the latest complete fiscal year. Denial rate across the window: 1.1%. Still actively attesting: 10 certified LCA filings in FY2026 — the freshest read on sponsorship intent, ahead of the slower petition record.

FY2020: 28 new · 40 renewalsFY2021: 8 new · 43 renewalsFY2022: 21 new · 36 renewalsFY2023 (prelim.): 1 new · 8 renewals

Petition approvals from the federal record — counts of approvals, not people; one person can hold multiple petitions across years. LCA filings are attestations, not hires. A fiscal year marked “prelim.” is still being published by USCIS and is left out of the trend. Read the trend, not the absolute size.

Benefits · DOL Form 5500 · FY2024

This employer sponsors a 401(k) plan in the federal benefit-plan record. Headcount and the match below read from its retirement plan on file — PFIZER SAVINGS PLAN.

Active plan participants: 29,469Employer contributions (the match): $552MEmployer 401(k) contributions per participant: $19K/yrParticipant deferrals: $594MBenefit plans filed: 11

Audited DOL Form 5500 filings for FY2024, which lag the calendar by roughly one to two years. Counts are PLAN PARTICIPANTS — covered employees plus separated staff still holding a balance — not a headcount, and are read from the single representative retirement plan, never summed across a sponsor’s plans. Employer contributions are the plan’s Schedule H line 2a (the match); a blank contribution line means it was not disclosed at this grain, not that it was zero. The absence of a line is never the absence of the benefit. Per-participant is employer 401(k) contributions divided by active participants for the latest filed year — a plan-wide average, not your match. What lands in your account depends on the plan formula, your own deferral rate and your salary; ask for the contribution schedule.

03 · Company quality

Whether the company can support the promise

This is the company-health read behind the offer: growth quality, operating discipline, market risk, and whether the financial base supports the compensation ask.

Rule of 40

8.2

Revenue growth

2.6%

Gross margin

72.8%

Revenue / employee

$849K

Trailing twelve months ÷ latest reported headcount.

Revenue mix

Biopharma Segment

97.8%

Segment Reporting, Reconciling Item, Corporate Nonsegment

2.2%

Latest reported segmentation, FY2025 · USD.

Where geographic revenue comes from

UNITED STATES

59.2%

Developed Rest Of World

25.9%

Emerging Markets

14.9%

Latest reported segmentation, FY2025 · USD.

Financial score read

Quality label

Healthy

Altman Z

2.1

Piotroski

Scores are treated as a screening signal only; they support, not replace, the operating metrics above.

Recent events that change the read

Stock News · Sep 14, 2026

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage

Stock News · Sep 14, 2026

Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?

Stock News · Sep 14, 2026

4 High-Yield Dividend Stocks Worth Having in Your Roth IRA

Source feeds are filtered to a short materiality read; the brief avoids raw news-feed dumps.

Strategic coherence

75/100

Strong

This connects transcript strategy, operating metrics, and offer timing. A coherent company story strengthens equity confidence; drift or mixed messaging shifts emphasis toward cash certainty and explicit role scope.

Growth quality

Your $215,000 base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203), and the headline package of $300,000 — base plus equity plus signing — is 1.8× that median, though the band excludes equity and bonus so the comparison is not apples-to-apples. Pfizer's composite growth-plus-FCF margin score of 8.2 trails the 7-peer Drug Manufacturers median revenue growth of 5.7% (YoY, 12 months ending 2026-06-28) while the company itself posted 2.6% YoY revenue growth over the same window — a meaningful gap that, combined with headcount declining from 88,000 (2023) to 75,000 (2025), signals an organization still in cost-reduction mode even as Q2 FY2026 revenue of $15.0B and a raised full-year guidance midpoint suggest the commercial trough may be passing. The FAIR verdict stands: your base is strong, but the $55,000 RSU grant on a 3-year vest is the thinnest component of the package — ask about refresh cadence, vesting structure, and whether the signing bonus carries a repayment obligation before you sign.

Evidence confidence: medium

Rule of 40

Rule of 40 score 8 — revenue growth 2.6% plus FCF margin 5.6%.

Evidence confidence: high

Stock volatility and drawdown

Annualized volatility 23.6%; max 12-month drawdown -17.1%; current drawdown -4.3%.

Evidence confidence: high

Strategic coherence

Strategic coherence: 75/100 (Strong). The strategic narrative shows a consistent focus on innovation, R&D, and market leadership, with a clear emphasis on growth areas such as oncology and obesity treatments. However, there are emerging risks related to competition and regulatory challenges that could impact future performance.

Evidence confidence: high

Consistent themes across quarters: Oncology, Obesity Treatments, R&D Pipeline Development, AI Integration.

Evidence confidence: high

Themes that vanished without resolution: Market Leadership, Acquisition Strategy, Cost Management.

Evidence confidence: medium

Disappeared themes may indicate strategic pivot or de-prioritization.

Newly appeared themes: Maximizing value from acquisitions, Leadership in next-generation therapies, Financial discipline and cost management.

Evidence confidence: medium

Strong focus on R&D and innovation suggests opportunities for growth and advancement in roles related to these areas.

Evidence confidence: high

Influence & federal exposure (LDA/SOPR · USAspending)

Reported lobbying spend of $22.65M across 47 LDA/SOPR filings (24 months). Primary issue codes: HCR (21), TAX (19), TRD (19), MMM (10), PHA (7).
$0.02M in federal obligations across 20 USAspending awards (24 months). Largest agencies: Department of Defense ($0.02M).

In their own words

Verbatim from the latest earnings call — management’s stated risks and investment priorities, unedited.

“Our commercial performance has also helped mitigate the impact of currently low COVID infection levels.”

Stated risk · Low COVID infection levels impacting revenue

“We continue to forecast significant risk-adjusted revenue in other non-small cell lung cancer indications, subject to technical and regulatory success.”

Stated risk · Regulatory risks

“With the addition of Seagen, we gained an innovative platform, deep scientific expertise and a promising ADC pipeline central to our goal of growing our oncology.”

Investment priority · Oncology

“We believe we are on a path towards unlocking a differentiated profile for patients with obesity and related conditions in a market expected to reach $150 billion.”

Investment priority · Obesity and related conditions

Rule of 40

8.2Rule of 40 · adapted screen

Below 40

040 line80

Revenue growth

+2.6%

FCF margin

+5.6%

Growth plus margin sits below the 40 line — growth is coming at the cost of margin (or vice versa). Lean toward cash and role-scope certainty over back-loaded equity.

Adapted screen: the growth-plus-margin composite reads across sectors, but the 40 threshold was set for software. Read the two components and the trend, not the pass/fail.

What it shows

Revenue growth and free-cash-flow margin combined into an operating-quality score.

Why it matters

It gives a quick read on whether growth is disciplined or being bought with weak margins.

How to use it

Use a strong score as support for a stronger equity or refresh ask.

Cash runway

Profitable or cash-generating — runway gauge not applicable

What it shows

How many quarters of cash coverage the company appears to have.

Why it matters

Cash stress changes negotiation posture and role risk.

How to use it

If runway is thin, prefer cash/signing certainty over back-loaded equity.

Revenue per employee

TTM$849K

What it shows

Trailing-twelve-month revenue divided by the latest reported headcount.

Why it matters

High productivity supports premium compensation; weak productivity can foreshadow cost pressure.

How to use it

Use strong productivity as support for a strategic-hire compensation argument.

Analyst targets versus price

What it shows

Current price against low, median, and high analyst target anchors.

Why it matters

It frames whether the market already prices in most of the upside.

How to use it

Use wide dispersion as a reason to derisk vesting or ask for more shares.

Market cap trend

What it shows

Recent company valuation trend from public market data.

Why it matters

It contextualizes equity timing and whether the offer arrives after a run-up or reset.

How to use it

Pair this with stock-risk metrics before accepting equity-heavy compensation.

04 · Role and career risk

What could make this role better or worse than it looks

This section turns leadership, insider, board, and market signals into career-risk context for the role you are considering — and carries the forward scenarios: the base case and the three forks this offer can take.

Is your role exposed

Confidence: low

low exposure

0 = insulated · 100 = high · a separate read from company health

Your role looks well-insulated on the public signals available.

▼ lowers

Revenue trend (segment proxy)

Company revenue is up 9.6% first-to-last across 6 available quarters (Q1 FY2025 → Q2 FY2026), a 15-month span, not a year-over-year rate, which lowers role exposure at the company level.

▲ raises

Leadership churn

1 executive departure in the last 12 months. · source

Wage-enforcement posture (U.S. DOL Wage & Hour)

Concluded U.S. DOL Wage & Hour cases, matched to this employer by name and aggregated. A clean record here is not a guarantee; a case filed under a differently-spelled entity may not be captured.

1 concluded U.S. DOL Wage & Hour case on record (most recent findings 2007-12-14).

Workplace-safety posture (U.S. OSHA)

U.S. OSHA inspection and citation history, matched to this employer by establishment name and aggregated. Most relevant for on-site, warehouse, or operational roles; a clean or empty record is common for office employers and is not a guarantee.

92 U.S. OSHA inspections on record across 19 states (most recent 2025-12-02).
67 citations, $18,795 in penalties.

Public records checked this run

Litigation (public court records)
Not assessed this run
Wage enforcement (U.S. DOL WHD)
On file — see detail above
Workplace safety (U.S. OSHA)
On file — see detail above
DOL debarment
None in the record

Limitations

No Item 2.05 restructuring 8-Ks matched this employer in the lookback window.
No public ATS board is mapped for this employer, so hiring velocity is unavailable.
Public court-records lookup was unavailable for this run — litigation posture is unassessed, not clean.
Segment-level revenue is rarely disclosed; the revenue signal uses the company total as a proxy.

Stock volatility

23.6%

Current drawdown

-4.3%

Insider pattern

Net Buying

Directors on record

C-suite tenure dashboard

Leadership graph (resolved): Cecile Guegan — Interim Chief Financial Officer (appointed 2026-08-16); Michael McDermott — Chief Global Supply and Quality Officer, Executive Vice President (since 2025); Douglas Lankler — Executive Vice President & Chief Legal Officer (since 2025); Chris Boshoff, MD, FRCP, FMedSci, Ph.D. — Chief Scientific Officer and President, Research & Development (since 2025); Andrew Baum, MA, BM ChB — Chief Strategy and Innovation Officer and Executive Vice President (since 2024); Aamir Malik — Executive Vice President & Chief U.S. Commercial Officer (since 2023); Alexandre de Germay — Chief International Commercial Officer, Executive Vice President (since 2023); Payal Sahni — Chief People Experience Officer, Executive Vice President (since 2022); David Denton — Executive Vice President & Chief Financial Officer (since 2022); Lidia Fonseca — Chief Digital and Technology Officer, Executive Vice President (since 2019); Albert Bourla, DVM, Ph.D. — Chief Executive Officer (since 2019); Payal Sahni Becher — Chief People Experience Officer & Executive Vice President

Evidence confidence: medium

8-K transition scan is stale; absence of transitions should not be interpreted as stability.

Insider trading intelligence

Of 100 Form 4 rows pulled for this issuer, 1 moved shares out in the trailing 90 days (open-market sales, tax withholding on vests, and gifts), of which 1 were open-market sale rows and 3 were open-market purchases. The 1 open-market sale row are per-price fills of 1 sale trade by 1 distinct seller — 3,278 shares ≈ $83.3K in total — a Form 4 reports one sale as multiple execution-price rows, so the trade count is the count of decisions. 7 filings carry a per-trade classification — a count of FILINGS over a different window, not a subset of the row counts above.

Evidence confidence: high

BOURLA ALBERT: option_exercise_hold (positive).

Evidence confidence: medium

DAMICO JENNIFER B.: opportunistic_sell (negative).

Evidence confidence: medium

Buckley Mortimer J: open_market_buy (positive).

Evidence confidence: medium

BLAYLOCK RONALD E: open_market_buy (positive).

Evidence confidence: medium

BOURLA ALBERT: open_market_buy (positive).

Evidence confidence: medium

If you regret this in 18 months

The most likely way this goes wrong is that Pfizer's ongoing cost-reduction program — which already eliminated roughly 13,000 employees between 2023 and 2025 — extends into the Clinical Data Science function as the company continues to absorb patent cliff headwinds and COVID revenue normalization, and the Director-level role is either eliminated, scope-reduced, or restructured under a permanent CFO whose budget priorities differ materially from the interim period under Cecile Guegan. With revenue growing at only 2.6% against a peer-group median of 5.7%, and a dividend payout ratio that has exceeded 1.0x for two consecutive fiscal years, Pfizer's financial flexibility to protect discretionary R&D data science headcount is constrained — meaning the Cambridge, MA hybrid seat could be among the first casualties of a second restructuring wave triggered by a pipeline setback or further COVID product revenue decline. The $30,000 signing bonus will have been spent, the $55,000 RSU grant will be only partially vested, and the 90th-percentile base will have provided little protection against a role elimination that leaves the candidate re-entering a market they left at peak leverage.

Evidence confidence: medium

Early warning signals

Pfizer announces a second formal restructuring or headcount reduction program — watch 8-K filings and press releases for any language referencing 'organizational simplification,' 'cost realignment,' or a new FTE target below 75,000, which would signal that Clinical Data Science is again in scope for cuts.

Evidence confidence: medium

A permanent CFO is named and, within one quarter of appointment, signals a shift in R&D investment priorities — monitor earnings call transcripts and investor day materials for any reduction in data science or digital health budget language, or explicit de-prioritization of the pipeline assets this role supports.

Evidence confidence: medium

Base case

Your $215,000 base sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, n=203), so the cash floor is genuinely strong — but the headline package of $300,000 (base plus equity plus signing) is 1.8× that base-cash median only because it folds in equity and a one-time signing bonus that the band itself excludes, making a direct above-band claim misleading. Against that package strength, Pfizer's composite of revenue growth (2.6% over the 12 months from 2025-06-29 to 2026-06-28) plus FCF margin produces a Rule of 40 score of 8.2 — well below the 40 threshold, and trailing the 7-peer Drug Manufacturers - General median revenue growth of 5.7% — which caps the upside confidence on the $55,000 RSU grant at current prices. The offer warrants negotiation before signing: the base is already at the high end of the band, so the most productive levers are the equity grant size, the target bonus percentage (not yet disclosed), and vesting cliff and refresh terms — all of which you should ask about explicitly.

Evidence confidence: medium

Reference class

No public reference class beyond market-data peers and SEC leadership transitions.

Evidence confidence: low — read the specifics as directional, not verified

Three forks

The three ways this role can go from here — the downside path, the base case, and the upside. Each fork carries a signal of its own direction or says plainly that none was extracted; a fork never borrows the nearest available sentence.

Bear

No downside-direction signal was extracted for this brief.

Base

No base-direction signal was extracted for this brief.

Bull

No upside-direction signal was extracted for this brief.

Leadership tape

Source-backed leadership facts are used conservatively; unresolved or sparse records are omitted from user-facing claims.

Cecile Guegan
2026-08-16
hire: role → Interim Chief Financial Officer
“will serve as Interim Chief Financial Officer”
Dave Denton
2026-08-15
departure: Chief Financial Officer → role
“he will step down from his current position as Chief Financial Officer”

Coverage note

Leadership

Ready

Board

Ready

8-K scan

Stale

8-K transition scan is stale; absence of transitions should not be interpreted as stability.

C-suite tenure

Dated appointments from SEC filings — earliest first. Officers without a filed start date are not shown, a start we could only date to a YEAR is shown as that year, and a seat length is computed only where the filing states when the role began. Rows marked “appointed” carry a transition-filing date, which dates the filing rather than the tenure. Where the filing does not say what its date is a date of, the officer is omitted rather than shown under a verb the record does not support.

Lidia Fonseca

Chief Digital and Technology Officer, Executive Vice President

since 2019 · 7y

Albert Bourla, DVM, Ph.D.

Chief Executive Officer

since 2019 · 7y

Payal Sahni

Chief People Experience Officer, Executive Vice President

since 2022 · 4y

David Denton

Executive Vice President & Chief Financial Officer

since 2022 · 4y

Aamir Malik

Executive Vice President & Chief U.S. Commercial Officer

since 2023 · 3y

Alexandre de Germay

Chief International Commercial Officer, Executive Vice President

since 2023 · 3y

Andrew Baum, MA, BM ChB

Chief Strategy and Innovation Officer and Executive Vice President

since 2024 · 2y

Michael McDermott

Chief Global Supply and Quality Officer, Executive Vice President

since 2025 · 1y

Insider intensity

What it shows

Form 4 buy/sell activity summarized by month.

Why it matters

Heavy selling does not automatically mean distress, but it changes how much equity risk you should accept.

How to use it

Use sustained selling as support for vest protection or more cash.

Institutional ownership

13F institutional ownership66.1%

3,087 institutional holders (latest 13F)

What it shows

How much of the float sits with institutions, and across how many holders.

Why it matters

Ownership mix can amplify volatility and market sensitivity.

How to use it

Treat concentrated ownership as another reason to stress-test equity-heavy offers.

Not available for this run: board interlocks and largest-holder position sizes. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.

05 · Employer durability

Employer durability versus peers

How this company's financial health reads against its public peers — every company scored on the identical rubric, from its own filings. This is a durability comparison, not a list of jobs you could take instead.

Financial health, one rubric

Every company below is scored by the same rule — Rule of 40, revenue growth, cash runway — from its own filings. No cross-company guessing.

PFE

AMGN

Rule of 40 basis: revenue growth over the 12.0 months from 2025-06-30 to 2026-06-30 plus FCF margin for the period ending 2026-06-30.

BMY

Rule of 40 basis: revenue growth over the 12.0 months from 2025-06-30 to 2026-06-30 plus FCF margin for the period ending 2026-06-30.

GILD

Rule of 40 basis: revenue growth over the 12.0 months from 2025-06-30 to 2026-06-30 plus FCF margin for the period ending 2026-06-30.

GSK

Rule of 40 basis: revenue growth over the 12.0 months from 2025-06-30 to 2026-06-30 plus FCF margin for the period ending 2026-06-30.

Peer universe: 10 vendor-listed candidates examined · 7 qualifying Drug Manufacturers - General peers · the first 4 shown below, in the vendor's order · every median on this panel is computed over all 7 qualifying peers, not only the 4 displayed.

Peer companies

Financial health on one rubric: PFE scores 43; peers — GILD 75, AMGN 71, GSK 60, BMY 58; peer median 71 across all 7 scored peers, of which 4 are listed here.

Evidence confidence: medium

Financial-health axis only — leadership, career, and role factors are not honestly comparable across companies from public filings alone.

Promotion and tenure reference class

No user-contributed tenure aggregate has passed k-anonymity for this company yet.

Evidence confidence: low — read the specifics as directional, not verified

06 · Negotiation playbook

How to use the brief in the conversation

This is the action layer: the asks to prioritize, the scripts to use, the questions to ask, and the dealbreakers to monitor.

How to negotiate this

Your base at $215,000 is already well above the Massachusetts market anchor for this role — pressing it further spends energy on a lever that doesn't need it. The real gap is in the equity grant, which at $55,000 over three years delivers roughly $18,333 a year in RSU value — thin for a Global Job Level 11 seat at a company that named AI-driven R&D acceleration a top strategic priority on its Q2 earnings call. Open the conversation by expressing genuine enthusiasm for the role and the pipeline, then make one clean ask: bring the equity grant to $63,000. That single move adds $2,667 to your recurring annual uplift and keeps the negotiation focused on the lever where Pfizer has the most room.

What you're asking for

$3K / yr

One-time bridge (signing)

$17K

Your counter, lever by lever

Base salary

non-cash lever

The counter-structure holds base at $215,000 — there is no ask on this lever. Your base already sits at the 90th percentile of the Massachusetts base-cash market band (median $162,634, p75 $187,975, n=203), which means pushing it further would spend your one meaningful ask on a lever that is already above the market anchor. Every dollar of negotiating energy belongs on equity and signing, where the offer genuinely underdelivers relative to the seniority and strategic scope of a Global Job Level 11 Clinical Data Science director.

hold — base is already placed above the market anchor; press scope, level and equity refresh instead

Equity grant

$55K → $63K (floor $55K)

The $55,000 RSU grant vests over three years, producing approximately $18,333 per year in equity value before any price movement — a figure that does not reflect the strategic weight Pfizer placed on AI and clinical data science in its Q2 2026 earnings call. The target is $63,000 (floor $55,000), adding $2,667 to annual recurring value. The equity scenario analysis puts the base-case RSU value at $53,494 at a $27 share price and the bear case at $51,513 at $26 — a narrow spread that reflects limited near-term price catalyst given 2.6% revenue growth over the twelve months from 2025-06-29 to 2026-06-28, against a peer-group median of 5.7% across 7 qualifying Drug Manufacturers - General peers. A larger grant compensates for that constrained upside without touching a base that already sits at the 90th percentile of the Massachusetts base-cash band (median $162,634, n=203).

computed equity room

Signing bonus

$30K → $47K (floor $30K)

The $30,000 signing bonus is a one-time bridge — once it clears, your annual run-rate is base plus whatever annual incentive Pfizer attaches to this level, and that bonus target is not in the offer as collected. The target signing is $47,000 (floor $30,000), an increment of $17,000 over what's already offered. Because signing is non-recurring and comes out of a different budget than base or equity, it is typically the lowest-friction ask when base is already at market. It also partially compensates for the equity risk you are absorbing: the stock carries annualized volatility of 23.6% and a max drawdown of -17.1%, and the RSU cliff, clawback terms, and refresh cadence are not yet in hand.

low-friction one-time ask, added to the signing already offered, when base is already at market

Scope, title & level

non-cash lever

The non-dollar asks here are as important as the dollar ones. Before signing, ask what the annual target bonus percentage is for Global Job Level 11 and how it has actually paid out over the last two years — the offer model runs on base alone until that number exists, and at $215,000 base, even a 15% target represents $32,250 per year. Also ask what change-of-control acceleration applies to unvested RSUs — single-trigger, double-trigger, or none — and get the answer in the plan document. With Pfizer operating without a permanent CFO as of your October 15 start date (Dave Denton stepped down August 15, 2026; Cecile Guegan is serving as Interim CFO), understanding the structural protections on your equity is not a formality — it is a material term.

non-cash lever: leveling, scope, and equity-refresh cadence

Scripts

Written to be sent as they are. Edit any of them before you copy.

Counter Offer — Equity GrantEmail

Hi [Recruiter name], Thank you so much for sending over the offer details — I've had a chance to review everything carefully, and I'm genuinely excited about this role. The work Pfizer is doing in oncology and the push into AI-driven drug development is exactly the kind of mission I want to be part of, and the Clinical Data Science function feels like the right place to contribute to that. I do want to be straightforward with you about one thing. The base and the signing bonus are both meaningful, and I appreciate them. Where I'd like to have a conversation is on the equity grant. At $55,000 over three years, the RSU component feels light relative to the scope of a Director-level seat and the strategic priority the company has placed on data science and AI. I'd like to ask whether we can bring the equity grant to $63,000. That's the one ask I'm making — I'm not looking to renegotiate everything, just to close that one gap. Is there flexibility there? I'd also love to understand the annual incentive target for this level before I sign — that piece wasn't included in the offer letter and it's an important part of how I'm thinking about the full picture. Looking forward to your thoughts.

Hi [Recruiter name],

Thank you so much for sending over the offer details — I've had a chance to review everything carefully, and I'm genuinely excited about this role. The work Pfizer is doing in oncology and the push into AI-driven drug development is exactly the kind of mission I want to be part of, and the Clinical Data Science function feels like the right place to contribute to that.

I do want to be straightforward with you about one thing. The base and the signing bonus are both meaningful, and I appreciate them. Where I'd like to have a conversation is on the equity grant. At $55,000 over three years, the RSU component feels light relative to the scope of a Director-level seat and the strategic priority the company has placed on data science and AI. I'd like to ask whether we can bring the equity grant to $63,000.

That's the one ask I'm making — I'm not looking to renegotiate everything, just to close that one gap. Is there flexibility there?

I'd also love to understand the annual incentive target for this level before I sign — that piece wasn't included in the offer letter and it's an important part of how I'm thinking about the full picture.

Looking forward to your thoughts.

Editable — tweak before you send

Verbal Counter — Equity, One NumberSay this

I really appreciate the offer, and I want to be clear that I'm excited about this — the role, the team, the direction the company is heading. I do want to raise one thing before I sign. The equity piece feels a little light for a Director-level seat given the scope of what this role owns. I'm not asking to renegotiate the whole package — I just want to ask whether we can bring the RSU grant to $63,000. That's the one number I'd like to close on. Is there room to get there?

Editable — tweak before you send

Best and Final — Holding at $63,000 EquityEmail

Hi [Recruiter name], I appreciate you going back to the team on this. I want to be direct: I'm committed to joining Pfizer, and I'm not trying to make this harder than it needs to be. But I do want to be honest that the equity grant is the one place where I feel the offer doesn't quite reflect the level of the role. I'm holding my ask at $63,000 on the RSU grant. I'm not moving off that number because it's not an aggressive ask — it's a reasonable reflection of what a Global Director seat in a function the company has called a strategic priority should carry. If the equity can't move, I'd ask that we revisit the signing bonus to help bridge the gap. I'm flexible on how we get there — I just want to make sure we land somewhere that works for both sides. I'm ready to sign as soon as we can close this. What can you do?

Editable — tweak before you send

Competing Offer — Conditional FrameSay this

I want to be upfront with you because I respect the process and I genuinely want this role. If I have another offer in hand when we're finalizing terms, I'll share that with you directly — I'm not going to use it as a pressure tactic, but it would be relevant context. What I can tell you right now is that the equity grant is the one place where I think there's a real gap, and I'd rather close it here than have to weigh it against something else. Can we get to $63,000 on the RSU grant?

Editable — tweak before you send

When they push back

“The base is already very strong for this role — we don't have room to move on total comp.”
I completely agree that the base is strong, and I'm not asking to move it. The one thing I'm asking about is the equity grant specifically — not the total package, just that one component. At $55,000 over three years, it's the piece that feels lightest relative to the scope of a Director-level seat. Can we look at whether there's room to bring the RSU grant to $63,000 without touching anything else?
“The equity grant is set by the band for your level — we can't go outside it.”
That makes sense, and I appreciate you explaining how it works. Can you help me understand whether there's any flexibility within the band, or whether a supplemental grant or a different structure is something that's been done at this level? I'm not asking you to break a policy — I just want to make sure I understand what options exist before I make a final decision.
“We can look at the signing bonus instead of the equity.”
I'm open to that conversation. If the equity grant can't move, I'd want to make sure the signing bonus meaningfully closes the gap — I'd be looking for something in the range of $47,000 total. Is that something the team can get to?
“This is our best and final offer.”
I hear you, and I want you to know I'm taking this seriously — I'm not trying to drag this out. The role is genuinely where I want to be. I just want to make sure I'm walking in feeling like the equity reflects the level of the work. If $63,000 on the RSU grant truly isn't possible, can we talk about what else might be available — whether that's the signing bonus, the bonus target clarity, or something else? I want to find a way to yes.
“We don't know what the bonus target is yet — that gets set after you start.”
I understand that some of that gets finalized once I'm in the system. Before I sign, though, can you at least tell me what the target bonus percentage is for this level as a matter of policy? I'm not asking for a guarantee — I just want to understand the structure so I can make an informed decision. That number is a meaningful part of how I'm thinking about the full annual picture.

Walk-away line

“I've genuinely valued this conversation, and I have real respect for the team and the work — but if the equity grant can't reach $63,000 and the signing bonus can't bridge the gap, I'm not in a position to accept the offer as it stands. I hope we can find a way to close this, and I'm happy to keep talking if there's flexibility I haven't seen yet.”

Targets are computed from your offer and a 5% base / 15% equity negotiation-room estimate, anchored to the DOL LCA market band for Massachusetts, where your base sits at roughly the 90th percentile. Base is held, not pushed: the deterministic market read places it above the anchor, so the uplift below comes from the levers that remain. They are derived deterministically, not written by the model.

Who to talk to — and in what order

Comp lives with different people than you think. Aim each ask at the person who can actually move it.

Recruiter

Owns the offer number and can move base / signing within a set band.

Your first channel. Make the case here: give them the market floor and one clear, specific ask. Stay warm — they're your messenger, not your obstacle.

Hiring manager

Owns level, scope, and the business case for hiring you.

Your advocate. Loop them in for a level bump, equity, or when the recruiter says the band is fixed — they can request an exception the recruiter can't.

Compensation team

Sets the salary bands; rarely negotiates with you directly.

You almost never talk to them. But the hiring manager can push an out-of-band exception up to them — which is why winning the manager matters.

When they say “this is our final offer”

01
“Final” is usually a close, not a wall. Stay gracious, restate your value in one line, and make a single specific, justified ask — not a list.
02
If base is capped, trade levers: pivot to a signing bonus, an equity refresh, an accelerated first review, or a title/level adjustment.
03
Only invoke a deadline or competing interest if it's real. A bluff that gets called costs you leverage and goodwill.
04
Give them an easy yes: name the one thing that turns a maybe into a signature today.

Say this

“I really want to make this work — I’m ready to sign. The one thing that would let me say yes today is [specific ask]. Is there any room there?”

Base sits at 90th percentile — equity is thin

Your $215,000 base clears the Massachusetts base-cash market band median of $162,634 by a wide margin and lands at the 90th percentile of that 203-observation band — so base is not where the gap lives. The $55,000 RSU grant is where the offer underdelivers relative to the seniority implied by Global Job Level 11: at a 3-year vest, that is roughly $18,333 in equity per year before any price movement, a figure that does not reflect the strategic weight Pfizer's own earnings call placed on AI-driven R&D acceleration — exactly the domain a Director of Clinical Data Science owns. Ask whether the equity grant can be increased to better reflect the level's scope.

Evidence anchor: COMP PLACEMENT (base percentile, band median); KNOWN OFFER TERMS (equity $55,000, vest 3 years); EARNINGS STRUCTURED (AI in R&D as investment area)

Signing bonus is one-time — ask about bonus target

The $30,000 signing bonus is a non-recurring payment; once it clears, your annual run-rate drops to base plus whatever annual incentive Pfizer attaches to this level. The offer as collected carries no target bonus percentage, which means a material component of your ongoing total compensation is unquantified. Before signing, ask what the annual incentive target is as a percentage of base for Global Job Level 11 — that figure, applied to $215,000, could represent $30,000–$50,000 or more per year and belongs in any honest comparison of this offer to alternatives.

Evidence anchor: KNOWN OFFER TERMS (signing $30,000, target bonus NOT PROVIDED); COMP PLACEMENT (headline $300,000 = base + equity + signing only)

Pfizer's Rule of 40 at 8.2 — equity upside is constrained

Pfizer's revenue grew 2.6% over the twelve months from 2025-06-29 to 2026-06-28, against a peer-group median of 5.7% across the 7 qualifying Drug Manufacturers - General peers examined. The composite of that growth rate and FCF margin of 5.6% produces a Rule of 40 score of 8.2 — a weak reading for a large-cap pharma, though the 40-point threshold is a SaaS convention and should be read as a composite signal rather than a pass/fail. The equity scenario analysis puts your bear-case RSU value at $51,513 (at a $26 share price) and the base case at $53,494 (at $27) — a spread of only $1,981 between bear and base, reflecting limited near-term price catalyst. The bull case reaches $68,348 only if the DCF fair value of $34.50 is realized. Use the constrained upside to argue for a larger grant size rather than a higher base.

Evidence anchor: COMPUTED METRICS (revenue growth 2.6%, peer median 5.7%, Rule of 40 8.2, FCF margin 5.6%, equity scenarios bear $51,513 / base $53,494 / bull $68,348, DCF $34.497)

CFO vacancy adds near-term uncertainty — ask about refresh

Dave Denton stepped down as CFO effective 2026-08-15, and Cecile Guegan was appointed Interim CFO on 2026-08-16. A permanent CFO search at a $158 billion market-cap company typically reshapes budget priorities and can affect discretionary comp decisions — including equity refresh cycles — at the director level. This brief carries no collected terms on equity refresh cadence, vesting cliff, or clawback. Before signing, ask explicitly: what is the refresh schedule for RSU grants at Global Job Level 11, and is there a retention grant or refresh commitment tied to this hire? The CFO transition makes that question more urgent, not less.

Evidence anchor: GRAPH CONTEXT (Denton departure 2026-08-15, Guegan interim appointment 2026-08-16); KNOWN OFFER TERMS (refresh cadence not collected)

Dividend payout ratio exceeds 100% — probe financial durability

Pfizer's FY2025 dividend payout ratio was 1.2575 — meaning the company paid out more in dividends than it earned in net income that year. The Altman Z-score stands at 2.085, which sits in the zone that warrants monitoring, and net debt to EBITDA is 4.93x. Headcount has fallen from 88,000 (2023 10-K) to 75,000 (2025 10-K), a reduction of 13,000 employees over two years, and a WARN filing recorded 100 additional separations in Washington state as recently as August 2025. None of this makes the offer unacceptable — the Piotroski score of 7 signals healthy near-term financial health — but it is a reasonable basis to ask whether the RSU grant can be front-weighted or whether a larger signing component can substitute for equity risk you are being asked to absorb at a moment of balance-sheet pressure.

Evidence anchor: FINANCIAL RATIOS FY2025 (payout ratio 1.2575, Altman Z 2.085, net debt/EBITDA 4.93); EMPLOYEE COUNT HISTORY (88,000 → 75,000); WARN WORKFORCE SIGNALS (100 workers, Aug 2025); COMPUTED METRICS (Piotroski 7)

Questions they cannot fake

1
What is the annual target bonus percentage for Global Job Level 11, and what did the bonus actually pay out at — as a percentage of target — for fiscal years 2024 and 2025?
Your offer letter states a $215,000 base but no bonus target. Until that figure exists, your headline package of $300,000 (base plus equity plus signing) is incomplete — the true annual run-rate could be materially higher or lower. Pfizer's FY2025 proxy shows named executives received incentive plan payouts ranging from $2.675M to $5.4M against disclosed salary bases, which tells you the company does pay performance bonuses at scale. You need the Level 11 target percentage and the actual payout history before you can evaluate whether the base-heavy structure of this offer is a feature or a gap.
2
What change-of-control acceleration applies to the $55,000 RSU grant — single-trigger, double-trigger, or none — and can you provide the plan document rather than a recruiter summary?
Pfizer's CFO departed in August 2026 and an interim CFO was appointed the same month, a leadership transition that signals the company is in active reorganization. In that environment, the treatment of unvested equity under a change-of-control scenario is not a theoretical question. The RSU grant vests over three years, so a significant portion will be outstanding for years after your October 2026 start. The plan document — not a verbal description — is the only authoritative source for whether those units accelerate, lapse, or convert in a transaction.
3
What is the equity refresh cadence and typical grant size at Level 11 — annual, biennial, or performance-triggered — and has that cadence changed during the current cost-reduction program?
The $55,000 RSU grant covers a three-year vest, but the offer carries no refresh commitment. Pfizer's reported headcount has declined from 88,000 at end-2023 to 75,000 at end-2025, a reduction of 13,000 employees, and a WARN filing recorded 100 additional separations in Washington state in August 2025. In a company actively managing headcount, refresh grants are not guaranteed, and the equity scenario modeled here — bear $51,513 at $26/share, base $53,494 at $27/share, bull $68,348 at the DCF-implied $34.50 — assumes the initial grant is the only one. Ask explicitly whether Level 11 directors receive annual refresh grants and whether the current program has altered that schedule.
4
Given that Pfizer's revenue grew 2.6% over the twelve months ending June 2026 — against a peer-group median of 5.7% across seven Drug Manufacturers — General peers — what is the merit-increase budget for Level 11 in 2027, and is there a band ceiling that would compress future base increases given that your $215,000 already sits at the 90th percentile of the Massachusetts base-cash market?
Your base is strong relative to the external market — the Massachusetts base-cash band runs from a p25 of $148,762 to a p75 of $187,975, and $215,000 clears the p75 by $27,025. That positioning is an asset on day one but a constraint on merit growth if Pfizer's internal band for Level 11 has a ceiling near your starting point. With revenue growth trailing the peer median by 3.1 percentage points and a composite growth-plus-FCF-margin score of 8.2, the company is operating under financial discipline — the Q2 2026 earnings call named cost management as an explicit priority. Understanding the merit budget and band ceiling now tells you whether the base can grow or whether future upside must come entirely from equity and bonus.

Dealbreakers to watch

CFO Departure Mid-Transition Creates Leadership Uncertainty
high
David Denton stepped down as CFO effective August 15, 2026, and Cecile Guegan was appointed Interim CFO on August 16, 2026 — meaning Pfizer enters your October 15 start date without a permanent finance chief. At Director level (Global Job Level 11), budget approvals, headcount decisions, and merit-cycle outcomes all flow through CFO-level sign-off. An interim in that seat during a cost-discipline phase — management cited 'financial discipline' as a 2026 strategic priority on the Q2 earnings call — creates real uncertainty about how quickly resource requests get resolved and whether the function you'd join has a stable financial sponsor. Ask who holds budget authority for Clinical Data Science during the transition and what the timeline is for a permanent CFO appointment.
Source ↗ · SEC Form 8-K / GRAPH CONTEXT: Dave Denton departure and Cecile Guegan interim appointment, both dated 2026-08-16
Sustained Headcount Reduction Signals Ongoing Restructuring Pressure
high
Pfizer's 10-K filings show headcount fell from 88,000 (period ending 2023-12-31) to 81,000 (2024-12-31) to 75,000 (2025-12-31) — a reduction of 13,000 employees, or roughly 15%, over two annual reporting periods. A separate WARN Act filing recorded 100 additional layoffs in Washington state as recently as August 25, 2025. The Q2 2026 earnings transcript confirms management continues to 'operate with financial discipline,' and the composite growth-plus-FCF-margin figure (revenue growth of 2.6% over the 12 months from 2025-06-29 to 2026-06-28, plus FCF margin of 5.6%, yielding 8.2) sits well below the 40 threshold used as a rough composite health screen — though that threshold is a SaaS convention and Pfizer is not SaaS, so treat it as a directional signal, not a pass/fail grade. Before signing, ask directly whether Clinical Data Science headcount is protected under current cost plans and whether the team has an approved headcount for FY2027.
Source ↗ · Pfizer 10-K filings (SEC EDGAR, periods 2023-12-31 through 2025-12-31); WARN Act filing, WA, 2025-08-25
Dividend Payout Ratio Exceeds 100% — Dividend Sustainability in Question
medium
Pfizer's FY2025 dividend payout ratio was 1.2575 (i.e., dividends paid exceeded net income), and the FY2024 ratio was 1.1860 — two consecutive years above 1.0x. The FY2025 dividend yield was 6.9%, which multiple analyst headlines from September 2026 characterize as masking a 'fragile dividend story.' A dividend cut would directly compress the stock price supporting your $55,000 RSU grant; the equity scenario values already reflect a bear case of $51,513 at a $26 share price versus the current $27.76. This is not a prediction of a cut, but the payout math warrants a direct question about the board's dividend policy and whether any restructuring of the dividend is under active review.
Source: Pfizer DEF 14A / FY2025 annual financial ratios (dividendPayoutRatio: 1.2575); Stock news: '24/7 Wall Street: Pfizer's 6% Yield Masks a Fragile Dividend Story,' 2026-09-14
Patent Cliff and COVID Revenue Dependency Create Near-Term Revenue Headwinds
medium
Analyst headlines as of September 14, 2026 explicitly flag 'COVID and patent cliff headwinds' as unresolved risks. Revenue grew only 2.6% over the 12 months from 2025-06-29 to 2026-06-28, against a peer-group median of 5.7% (median across 7 qualifying Drug Manufacturers - General peers). Excluding COVID products, Q2 2026 operational revenue growth was 5% per the earnings transcript — meaning the non-COVID base is growing, but the COVID drag is material and the patent cliff compounds it. For a Director in Clinical Data Science, this matters because pipeline investment decisions — which directly determine the scope and priority of your work — are downstream of revenue trajectory. Ask which therapeutic areas are prioritized for data science investment in the 2027 operating plan and whether the Clinical Data Science function is aligned to the oncology and obesity programs management cited as growth vectors.
Source ↗ · Pfizer Q2 2026 earnings transcript (EARNINGS STRUCTURED); Zacks Investment Research headline, 2026-09-14: 'Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?'

Pre-mortem: what would make this offer fail

These are the brief’s highest-friction warnings converted into diligence prompts before you sign.

1
One dealbreaker check was dropped: its question or its signal did not fit the panel's length budget on a sentence boundary, and half a question is not a question.

Canonical action signals

Highest leverage asks

Evidence confidence: medium

Questions they cannot fake

What is the annual target bonus percentage for Global Job Level 11, and what did the bonus actually pay out at — as a percentage of target — for fiscal years 2024 and 2025? Why: Your offer letter states a $215,000 base but no bonus target. Until that figure exists, your headline package of $300,000 (base plus equity plus signing) is incomplete — the true annual run-rate could be materially higher or lower. Pfizer's FY2025 proxy shows named executives received incentive plan payouts ranging from $2.675M to $5.4M against disclosed salary bases, which tells you the company does pay performance bonuses at scale. You need the Level 11 target percentage and the actual payout history before you can evaluate whether the base-heavy structure of this offer is a feature or a gap.

Evidence confidence: medium

What change-of-control acceleration applies to the $55,000 RSU grant — single-trigger, double-trigger, or none — and can you provide the plan document rather than a recruiter summary? Why: Pfizer's CFO departed in August 2026 and an interim CFO was appointed the same month, a leadership transition that signals the company is in active reorganization. In that environment, the treatment of unvested equity under a change-of-control scenario is not a theoretical question. The RSU grant vests over three years, so a significant portion will be outstanding for years after your October 2026 start. The plan document — not a verbal description — is the only authoritative source for whether those units accelerate, lapse, or convert in a transaction.

Evidence confidence: medium

What is the equity refresh cadence and typical grant size at Level 11 — annual, biennial, or performance-triggered — and has that cadence changed during the current cost-reduction program? Why: The $55,000 RSU grant covers a three-year vest, but the offer carries no refresh commitment. Pfizer's reported headcount has declined from 88,000 at end-2023 to 75,000 at end-2025, a reduction of 13,000 employees, and a WARN filing recorded 100 additional separations in Washington state in August 2025. In a company actively managing headcount, refresh grants are not guaranteed, and the equity scenario modeled here — bear $51,513 at $26/share, base $53,494 at $27/share, bull $68,348 at the DCF-implied $34.50 — assumes the initial grant is the only one. Ask explicitly whether Level 11 directors receive annual refresh grants and whether the current program has altered that schedule.

Evidence confidence: medium

If you regret this in 18 months

Evidence confidence: medium

Early warning signals

Evidence confidence: medium

Not available for this run: exit terms on the public record. Every stream we checked — rendered, held, or absent — is itemized in the appendix coverage matrix.

Purchase your report to unlock full details

Live SEC filings, peer comp, scripts, provenance, and canonical synthesis — built for your company and offer.

Get the Offer Brief — $49 Compare both brief tiers

What this brief covers — and what it can’t

Covered, with receipts

Public-company evidence: financial health and trajectory, leadership and board signals, role-level exposure (restructuring filings, WARN notices), the citable market wage band, insider filing patterns, and the negotiation math built from them.

Not in public filings

Your future manager and team, day-to-day culture, benefit terms the filings don’t carry (the 401k match formula, PTO, parental leave, healthcare costs), and private-company comparisons. Where a DOL Form 5500 filing matched, the plan-level 401k facts appear above — the day-to-day terms still don’t. That’s what the verification questions in §6 are for — ask them before you sign.

Appendix

Evidence and methodology

The main brief stays readable; the supporting facts, confidence map, source logs, methodology, and export preview live here for auditability.

Supporting facts

Form 4 rows examined

100

Validated 8-K transition rows

Validation issues

Confidence and data gaps

55% of the trajectory weighting is not evidence-backed (30% renormalized out of the composite, 25% scored on a neutral prior).

Sources cross-referenced

SEC filings analyzed · 10-K/Q, 8-K, proxy

Transcript & filing facts

100

Form 4 insider rows

Leadership / board records

Layoff / WARN signals

152

Records cited · total

Data coverage

This tracks whether available evidence is rendered, held for methodology, gated by confidence, or unavailable.

Canonical verdict and one-number model

Rendered

Canonical

Rendered in the executive decision screen.

Canonical section claims

Rendered

Canonical · 45 items

Rendered across the guided chapters as concise evidence cards.

Supporting facts and methodology notes

Appendix Only

Canonical · 28 items

Kept in the appendix so the main report stays readable.

Revenue product and geographic segmentation

Rendered

Fetched · 5 items

Top segments are rendered in Company Quality; full rows remain source data.

Analyst estimates, grades, DCF, targets, earnings

Rendered

Fetched

Rendered as market-consensus cards instead of raw analyst feeds.

News, press releases, and M&A events

Rendered

Fetched · 6 items

Material recent events are summarized; raw feed clutter is omitted from the main flow.

Ownership concentration and financial health scores

Rendered

Fetched

Rendered in Role and Career Risk when it changes the risk read.

Career signal layer leadership and board coverage

Rendered

Computed

Rendered as leadership tape, coverage note, and board count.

O*NET, BEA, WARN, SEC facts, lobbying, USAspending, FEC

Rendered

Open Data · 5 items

Verified public-data facts are rendered through canonical claims and the evidence appendix.

Evidence appendix

Evidence behind the dossier: supporting facts, methodology, confidence rationale, filing logs, and exportable rows. Empty sections describe what was reviewed rather than silently disappearing.

Facts

100

Insider records

8-K records

Validation issues

What those validation issues are

8 findings from the seal-time checks; 8 advisory (the brief ships and a human reviews). Anything that could make a claim untrue blocks the seal and never reaches this page.

The same sentence appears several times across the brief — a readability note, not a factual one.
A figure is restated more often than this brief's editorial rules allow — a readability note, not a factual one.

Supporting facts(28)

Quarterly revenue (Q1 FY2025): $13715.0M.
Company financial statements · high confidence · Q1 FY2025
Quarterly revenue (Q2 FY2025): $14653.0M.
Company financial statements · high confidence · Q2 FY2025
Quarterly revenue (Q3 FY2025): $16654.0M.
Company financial statements · high confidence · Q3 FY2025
Quarterly revenue (Q4 FY2025): $17557.0M.
Company financial statements · high confidence · Q4 FY2025
Quarterly revenue (Q1 FY2026): $14451.0M.
Company financial statements · high confidence · Q1 FY2026
Rule of 40 score: 8.2. Revenue growth 2.6% + FCF margin 5.6%.
Computed market metrics · high confidence · 2026-09-14T16:49:47.680Z
Revenue per employee: $849K (+7.8% YoY).
Computed market metrics · medium confidence · 2026-09-14T16:49:47.680Z
Insider activity (90d): 1 open-market sell trade by 1 distinct seller — 3,278 shares ≈ $83.3K, filed as 1 per-price fill row, 3 open-market buy trades, sell share of trades 25%. Excluded as non-discretionary: 12 equity awards, 0 tax-withholding, 0 gifts. Pattern: net_buying. Signal: positive (low).
Form 4 insider activity · medium confidence · 2026-09-14T16:52:48.211Z
Equity scenario base case: analyst median implies $53,494 for the supplied grant.
Equity scenario model · high confidence · 2026-09-14T16:49:47.680Z
12-month stock risk: annualized volatility 23.6%, max drawdown -17.1%, current drawdown -4.3%.
Historical price model · high confidence · 2026-09-14T16:49:47.680Z
Cecile Guegan hire: Interim Chief Financial Officer.
SEC 8-K leadership event · medium confidence · 2026-08-16
https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm
Dave Denton departure: Chief Financial Officer.
SEC 8-K leadership event · medium confidence · 2026-08-15
https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm
Board: 12 directors (11 of 12 independent).
Proxy statement board record · medium confidence · 2026
https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htm
SEC filing: 4 filed 2026-09-01 00:00:00.
SEC filing index · medium confidence · 2026-09-01 00:00:00
https://www.sec.gov/Archives/edgar/data/78003/000122520826007499/xslF345X06/doc4.xml
SEC filing: N-PX filed 2026-08-31 00:00:00.
SEC filing index · medium confidence · 2026-08-31 00:00:00
https://www.sec.gov/Archives/edgar/data/78003/000007800326000111/xslN-PX_X01/primary_doc.xml
SEC filing: 3 filed 2026-08-28 00:00:00.
SEC filing index · medium confidence · 2026-08-28 00:00:00
https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/xslF345X06/doc3.xml
Strategic coherence: 75/100 (Strong). Strong focus on R&D and innovation suggests opportunities for growth and advancement in roles related to these areas.
Earnings call transcript · high confidence · 2026-09-14T16:52:48.211Z
Lobbying exposure: $22.65M reported over 47 filings. Top issues: HCR, TAX, TRD, MMM, PHA.
Public lobbying disclosure · medium confidence · 2026-09-14T16:52:48.211Z
Federal contract exposure: $0.02M obligated across 20 awards. Top agencies: Department of Defense.
Federal contract disclosure · medium confidence · 2026-09-14T16:52:48.211Z
BOURLA ALBERT: option_exercise_hold (positive).
Insider activity classification · medium confidence · 2026-08-31

Confidence map(8)

comp_reality · high Section has source-backed facts available.
leverage · medium Section has source-backed facts available.
leadership_stability · medium 8-K transition scan is stale; absence of transitions should not be interpreted as stability.
three_questions · medium Section has source-backed facts available.
counterfactual · low Counterfactual recommender needs alumni outcomes and peer score generation.
five_year_forecast · low No released career-path aggregate buckets for this role family; the reference class here is public only — market peers and SEC leadership transitions.
organizational_diagnosis · medium Section has source-backed facts available.
red_flags · medium One dealbreaker check was dropped: its question or its signal did not fit the panel's length budget on a sentence boundary, and half a question is not a question.

Methodology(11)

Trajectory Score weights organizational health, leadership stability, strategic coherence, alumni outcomes, promotion velocity, skills marketability, and role-specific risk.
One Number model varies by report mode: NPV for offer evaluation, EV delta for stay-or-go, trajectory percentile for job seekers, CCVI for career trajectory.
Public-source leadership signals come from SEC 8-K and DEF 14A records when available.
Leadership coverage: stale. Leadership=ready, board=ready, transitions=stale. 12 leadership roles, 12 directors, 2 transition records.
Ticker: PFE. Company: Pfizer Inc.
Offer inputs: base $215,000, signing $30,000, equity $55,000.
No user-contributed tenure aggregates available.
Career-path aggregates use optional user contributions; this report scores public filings only.
Cross-section findings are AI-generated from assembled Tier 2 data and validated for multi-section citation.
Pre-mortem output was generated by Footnote's structured risk model.
Insider sentiment aggregate was not available for this ticker.

8-K leadership log(2)

[
  {
    "new_role": "Interim Chief Financial Officer",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm",
    "former_role": null,
    "person_name": "Cecile Guegan",
    "source_quote": "will serve as Interim Chief Financial Officer",
    "effective_date": "2026-08-16",
    "prior_employer": "Pfizer",
    "transition_type": "hire"
  },
  {
    "new_role": null,
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm",
    "former_role": "Chief Financial Officer",
    "person_name": "Dave Denton",
    "source_quote": "he will step down from his current position as Chief Financial Officer",
    "effective_date": "2026-08-15",
    "prior_employer": null,
    "transition_type": "departure"
  }
]

Insider trading log(100)

[
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007499/0001225208-26-007499-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-09-01",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 784012,
    "transactionDate": "2026-08-31",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 21,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Common Stock",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 149505,
    "transactionDate": "2026-08-17",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 0,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 25.75,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2030-03-04",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 33051,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 26.58,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2031-03-03",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 15748,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 26.89,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2031-02-27",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 11867,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 31.31,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2027-02-27",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 9603,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 33.82,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2028-02-25",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 9102,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 42.3,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2030-02-23",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 9758,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007363/0001225208-26-007363-index.htm",
    "price": 45.96,
    "symbol": "PFE",
    "formType": "3",
    "companyCik": "0000078003",
    "filingDate": "2026-08-28",
    "typeOfOwner": "officer: Executive Vice President",
    "reportingCik": "0002151218",
    "securityName": "Stock Appreciation Rights",
    "reportingName": "Guegan Cecile",
    "securitiesOwned": 0,
    "transactionDate": "2029-02-24",
    "transactionType": "",
    "directOrIndirect": "D",
    "securitiesTransacted": 6868,
    "acquisitionOrDisposition": ""
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007145/0001225208-26-007145-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-17",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 785060,
    "transactionDate": "2026-08-14",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 22,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007083/0001225208-26-007083-index.htm",
    "price": 26.34,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-12",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Common Stock",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 429173,
    "transactionDate": "2026-08-12",
    "transactionType": "P-Purchase",
    "directOrIndirect": "D",
    "securitiesTransacted": 38000,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826007004/0001225208-26-007004-index.htm",
    "price": 25.4,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-06",
    "typeOfOwner": "officer: SVP & Controller",
    "reportingCik": "0001805617",
    "securityName": "Common Stock",
    "reportingName": "DAMICO JENNIFER B.",
    "securitiesOwned": 28611,
    "transactionDate": "2026-08-05",
    "transactionType": "S-Sale",
    "directOrIndirect": "D",
    "securitiesTransacted": 3278,
    "acquisitionOrDisposition": "D"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006944/0001225208-26-006944-index.htm",
    "price": 25.46,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-05",
    "typeOfOwner": "director",
    "reportingCik": "0001214686",
    "securityName": "Common Stock",
    "reportingName": "BLAYLOCK RONALD E",
    "securitiesOwned": 66938,
    "transactionDate": "2026-08-05",
    "transactionType": "P-Purchase",
    "directOrIndirect": "D",
    "securitiesTransacted": 39231,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006943/0001225208-26-006943-index.htm",
    "price": 25.52,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-05",
    "typeOfOwner": "director",
    "reportingCik": "0002041310",
    "securityName": "Common Stock",
    "reportingName": "Buckley Mortimer J",
    "securitiesOwned": 37632,
    "transactionDate": "2026-08-05",
    "transactionType": "P-Purchase",
    "directOrIndirect": "D",
    "securitiesTransacted": 37632,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006900/0001225208-26-006900-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-08-03",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 786154,
    "transactionDate": "2026-07-31",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 24,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006638/0001225208-26-006638-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-07-16",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 772901,
    "transactionDate": "2026-07-15",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 24,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006587/0001225208-26-006587-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-07-13",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 772938,
    "transactionDate": "2026-07-09",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 84,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006273/0001225208-26-006273-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-07-01",
    "typeOfOwner": "director, officer: Chairman & CEO",
    "reportingCik": "0001595703",
    "securityName": "Phantom Stock Units SSP",
    "reportingName": "BOURLA ALBERT",
    "securitiesOwned": 772979,
    "transactionDate": "2026-06-30",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 25,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006260/0001225208-26-006260-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-06-30",
    "typeOfOwner": "director",
    "reportingCik": "0002041310",
    "securityName": "Phantom Stock Units",
    "reportingName": "Buckley Mortimer J",
    "securitiesOwned": 26335.128,
    "transactionDate": "2026-06-26",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 1543.845,
    "acquisitionOrDisposition": "A"
  },
  {
    "url": "https://www.sec.gov/Archives/edgar/data/78003/000122520826006259/0001225208-26-006259-index.htm",
    "price": 0,
    "symbol": "PFE",
    "formType": "4",
    "companyCik": "0000078003",
    "filingDate": "2026-06-30",
    "typeOfOwner": "director",
    "reportingCik": "0001633137",
    "securityName": "Phantom Stock Units",
    "reportingName": "Echevarria Joseph",
    "securitiesOwned": 165631.508,
    "transactionDate": "2026-06-26",
    "transactionType": "A-Award",
    "directOrIndirect": "D",
    "securitiesTransacted": 1904.076,
    "acquisitionOrDisposition": "A"
  }
]

Transcript pull(6)

“Maximizing the value of key transactions · Advancing R&D pipeline · Driving financial discipline and cost management · Investing in growth and innovation · Utilizing AI for R&D and operational efficiency”
Investment priority
“Our commercial performance has also helped mitigate the impact of currently low COVID infection levels.”
Stated risk · Low COVID infection levels impacting revenue
“We continue to forecast significant risk-adjusted revenue in other non-small cell lung cancer indications, subject to technical and regulatory success.”
Stated risk · Regulatory risks
“With the addition of Seagen, we gained an innovative platform, deep scientific expertise and a promising ADC pipeline central to our goal of growing our oncology.”
Investment priority · Oncology
“We believe we are on a path towards unlocking a differentiated profile for patients with obesity and related conditions in a market expected to reach $150 billion.”
Investment priority · Obesity and related conditions
“The acquisition of Biohaven positioned our company as a leader in providing treatment options for migraine, a disease affecting an estimated 1.2 billion people worldwide.”
Investment priority · Migraine treatment

Glossary(4)

8-K: SEC current report used for material company events, including executive appointments and departures.
DEF 14A: Definitive proxy statement containing board, governance, and executive disclosure.
Trajectory Score: Footnote's 0-100 estimate of career value and risk for a role/company decision.
K-anonymity: Privacy threshold that suppresses aggregate user-contributed metrics until enough contributors exist.

Export preview

CSV preview — first 10 rows of 28, exactly as the download serializes them.

id,claim,value,source_type,confidence
fact_001,Quarterly revenue (Q1 FY2025): $13715.0M.,13715000000,fmp_financials,high
fact_002,Quarterly revenue (Q2 FY2025): $14653.0M.,14653000000,fmp_financials,high
fact_003,Quarterly revenue (Q3 FY2025): $16654.0M.,16654000000,fmp_financials,high
fact_004,Quarterly revenue (Q4 FY2025): $17557.0M.,17557000000,fmp_financials,high
fact_005,Quarterly revenue (Q1 FY2026): $14451.0M.,14451000000,fmp_financials,high
fact_006,Rule of 40 score: 8.2. Revenue growth 2.6% + FCF margin 5.6%.,8.2,derived_fmp,high
fact_007,Revenue per employee: $849K (+7.8% YoY).,849280,derived_fmp,medium
fact_008,"Insider activity (90d): 1 open-market sell trade by 1 distinct seller — 3,278 shares ≈ $83.3K, filed as 1 per-price fill row, 3 open-market buy trades, sell share of trades 25%. Excluded as non-discretionary: 12 equity awards, 0 tax-withholding, 0 gifts. Pattern: net_buying. Signal: positive (low).",0.25,fmp_insider_trading,medium
fact_009,"Equity scenario base case: analyst median implies $53,494 for the supplied grant.",53494,derived_equity_scenario,high
fact_010,"12-month stock risk: annualized volatility 23.6%, max drawdown -17.1%, current drawdown -4.3%.",'-17.1,derived_price_history,high

JSON export contents (keys): facts, sections